Microbion Corporation

At Microbion, we are developing a new class of therapeutic drugs to tackle the unmet needs of rare, chronic, and serious diseases. Our lead drug candidate, pravibismane, is a first-in-class therapeutic with a novel triad of activities: anti-infective, antibiofilm, and anti-inflammatory. These synergistic properties uniquely position pravibismane to address conditions where conventional treatments often fail. We are advancing multiple pravibismane formulations through clinical development, focusing on indications with significant unmet needs: - Topical pravibismane for diabetic foot ulcers/infections: Phase 3 studies planned for 2025 - Local/surgical pravibismane for orthopedic infections: Phase 2a studies completed - Inhaled pravibismane for pulmonary diseases including Nontuberculous mycobacteria lung infections: Ready for first-in-human Phase 1 studies Pravibismane has been granted FDA Qualified Infectious Disease Product (QIDP), Fast Track, and Orphan Drug designations, underscoring its disruptive potential. To date, pravibismane development has been supported by over $22M in grants awarded from leading organizations, including the U.S. Department of Defense, NIH, CARB-X, and the Cystic Fibrosis Foundation. We are actively seeking strategic licensing and development partners to advance Phase 3 trials, explore new indications (e.g., immunomodulation and inflammation), and bring pravibismane to patients worldwide.

Website

http://www.microbioncorp.com

External link for Microbion Corporation

Industry

Pharmaceutical Manufacturing

Company size

2-10 employees

Headquarters

Bozeman, Montana

Type

Privately Held

Founded

2000

Specialties

Biotechnology, Medical device coatings, and Pharmaceutical drugs